Register for IndieBio New York’s Investor Showcase – March 11, 2026

Vitarka Therapeutics

Targeting the undruggable

Team

Vineeta Tripathi

CEO

Company details

A new wave of RNA therapeutics has the potential to transform treatment for solid tumours. Existing non-viral technologies cannot target tumour cells. Moreover, these fail to release the therapeutic RNA into the cytosol, less than 1% leaks out of the endosomes (a sub-cellular compartment). The remaining 99% is degraded.

EndoPore is Vitarka Therapeutics’ solution to this drug delivery problem. Using a synthetic biology approach, our team has developed pore forming proteins (PFPs) for targeted, cytosolic delivery of RNA therapeutics. PFPs have a naturally evolved mechanism of endosomal escape, which we are exploiting along with using a validated mechanism of stabilising RNA.

Get In Touch with Vitarka Therapeutics

Please tell us a little bit about yourself and why you'd like to get connected. Vitarka Therapeutics + SOSV will follow up with you via email.

Hidden
Hidden
Hidden
Hidden

No Offer, Solicitation, Advice, or Recommendation

Except to the extent expressly set forth in materials as may be provided through a password protected area on the SOSV website (the "Materials"), or as otherwise expressly specified by SOSV in writing, nothing on the SOSV website or on any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, is intended to constitute (i) an offer, or solicitation of an offer, to purchase or sell any security, other asset or service, (ii) investment advice or an offer to provide such advice, or (iii) a basis for making any investment decision. Except as expressly stated by SOSV in writing, neither the SOSV website or any platform or other communications medium owned, operated or otherwise by or on behalf of SOSV, nor any of the Materials make any effort to present a comprehensive or balanced description of SOSV or its investment activities. Please note the SOSV Communication Policy available here.